Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
List Prezesa Zarządu
Regulatory Filings Classification · 95% confidence The document text provided is heavily truncated and appears to be the raw HTML/CSS structure generated by a PDF conversion tool (pdf2htmlEX), indicated by tags like 'html', 'head', 'title', and extensive CSS styling. The title tag, 'phr_pismo_prezesa-2024-12-31-0-pl.xhtml', suggests a 'Letter from the President' or similar official communication, dated December 31, 2024, in Polish ('pl'). Given the nature of the content being a converted document structure rather than the content itself, and the title suggesting a formal communication, it is most likely a regulatory filing or a letter that doesn't fit neatly into the specific financial report categories (10-K, IR, ER). Since it is a formal document structure, and without clear content indicating a specific report type (like an earnings release or annual report), the most appropriate fallback category is Regulatory Filings (RNS). The document length is substantial (133k chars), suggesting it is the full content, not just an announcement, but the content itself is unreadable due to formatting artifacts.
2025-03-31 Polish
Zawarcie umowy na opracowanie i walidację metod analizy przyszłego wyrobu medycznego na trudno gojące się rany - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is a formal announcement referencing previous reports (raport bieżący nr 17/2023 and nr 10/2024) and detailing a new agreement (zawarcie umowy) for developing and validating an analytical method for a new medical device. It discusses the market size and potential positive impact on the issuer's financial results and development prospects. This structure—providing an update on a significant business development, often related to R&D or strategic projects, and referencing prior disclosures—is characteristic of ongoing regulatory disclosures in Polish markets (indicated by 'ESPI' system references). Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change, and it is a substantive update on a business matter, it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, required regulatory disclosure that doesn't match the more specific categories like DIRS, DIV, or CAP. Given the short length and the nature of providing an update on a project, RNS is the most appropriate fallback.
2025-03-18 Polish
Zawarcie umowy na opracowanie i walidację metod analizy przyszłego wyrobu medycznego na trudno gojące się rany
Regulatory Filings Classification · 100% confidence The document is written in Polish and references previous 'raport bieżący' (current report) numbers (17/2023 and 10/2024) published via the ESPI system. It details a specific operational update: the signing of an agreement for developing and validating an analytical method for a new medical device. This type of specific, material operational update that doesn't fit neatly into standard financial reports (like 10-K, IR, ER) or governance documents (like DEF 14A, CGR) is typically classified as a general regulatory announcement or filing. Since it is a specific, non-standard update about project progress and contractual agreements, and given the available options, the most appropriate general category for such specific regulatory disclosures that aren't standard financial reports is 'Regulatory Filings' (RNS). The document length is short (1701 chars), but it is providing substantive information, not just announcing the publication of another document, thus avoiding the RPA classification.
2025-03-18 Polish
Informacja o postępie projektu oceny skuteczności 1-MNA w łuszczycy - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1257 characters) written in Polish. It references a previous current report ('raport bieżący nr 11/2024') and informs the market that a research project ('projekt badawczy') timeline has been extended due to slow recruitment. It discusses the nature of the disease (psoriasis) and states that further stages will be reported in subsequent current reports. Since this is an update on a specific project/development that doesn't fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, CAP, M&A), and it is an announcement regarding ongoing operational/research progress, it best fits the general 'Regulatory Filings' category as a miscellaneous regulatory update, or potentially a Legal/LTR if the project was regulatory in nature, but given the context of research progress updates, RNS is the most appropriate fallback for non-standard, material operational news.
2025-02-05 Polish
Informacja o postępie projektu oceny skuteczności 1-MNA w łuszczycy
Regulatory Filings Classification · 95% confidence The document is a short announcement (1231 characters) written in Polish, referencing a previous current report (raport bieżący nr 11/2024) regarding a research project (1-MNA in psoriasis). It states that the research timeline has been extended due to slower recruitment. It discusses the nature of the disease (psoriasis) and the potential positive impact of successful results on the issuer's future development. Since this is an update on a specific ongoing project, likely related to R&D or clinical trials, and it is not a full financial report (10-K, IR), an earnings release (ER), or a formal legal notice, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not a specific announcement about management change (MANG), director dealing (DIRS), dividend (DIV), or capital change (CAP). Given its nature as an update on a specific operational/research matter, RNS is the most appropriate fallback.
2025-02-05 Polish
Terminy publikacji raportów okresowych w roku 2025 - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text, written in Polish, explicitly outlines the schedule for publishing periodic reports (annual, quarterly, semi-annual) for the upcoming year (2025). It details the dates for the annual report (raport roczny), Q1, H1, and Q3 quarterly reports. Crucially, it also states that changes to these dates will be announced via a current report ('raport bieżący'). This document is not the report itself (like 10-K or IR), but rather an announcement detailing *when* future reports will be released. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2025-01-13 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.